Date |
Product |
Disease |
Phase |
Company |
Therapeutic area |
2015-10-06
|
BT-063 |
systemic lupus erythematosus (SLE) |
2a |
Biotest (Germany) |
Autoimmune diseases |
2015-10-06
|
IPH2201 (anti-NKG2A antibody) and ibrutinib |
relapsed or refractory chronic lymphocytic leukemia |
|
Innate Pharma (France) AstraZeneca (UK) |
Cancer - Oncology |
2015-10-06
|
duvelisib |
indolent non-Hodgkin lymphoma |
2 |
Infinity Pharmaceuticals (USA - MA) |
Cancer - Oncology |
2015-10-06
|
OTI-15-01 |
chronic diabetic foot ulcers |
3 |
Osiris Therapeutics (USA - MD) |
Metabolic diseases - Cardiovascular diseases |
2015-10-05
|
Viaskin® Peanut |
peanut allergy |
2b |
DBV Technologies (France) |
Allergic diseases - Immunological diseases |
2015-10-05
|
PINTA 745 |
chronic kidney disease |
preclinical |
Atara Biotherapeutics (USA - CA) |
Kidney diseases - Renal diseases |
2015-10-05
|
PINTA 745 |
obesity, type II diabetes |
preclinical |
Atara Biotherapeutics (USA - CA) |
Metabolic diseases |
2015-10-05
|
PRX-106 (biosimilar version of etanercept) |
NASH (non-alcoholic steatohepatitis) |
preclinical |
Protalix BioTherapeutics (Israel) |
Liver diseases - Hepatic diseases |
2015-10-05
|
ONS-1045 (biosimilar version of bevacizumab - Avastin®) |
|
1 |
Oncobiologics (USA - NJ) |
Cancer - Oncology |
2015-10-05
|
M923, a biosimilar version of Humira® (adalimumab) |
chronic plaque psoriasis |
3a |
Momenta Pharmaceuticals (USA - MA) Baxalta (USA - IL) |
Autoimmune diseases – Dermatological diseases |
2015-10-05
|
SCY-078 ((1,3)-ß-D-glucan synthesis inhibitor) |
vulvovaginal candidiasis |
2 |
Scynexis (USA - NJ) |
Infectious diseases |
2015-10-02
|
bamosiran (SYL040012) |
ocular hypertension associated with glaucoma |
2b |
Sylentis (Spain) |
Ophtalmological diseases |
2015-10-01
|
TAK-831 |
schizophrenia, cerebellar ataxia |
1 |
Takeda Pharmaceutical (Japan) |
CNS diseases - Mental diseases |
2015-10-01
|
T cell receptor (TCR) product candidate targeting HPV-16 E6 |
|
|
Kite Pharma (USA - CA) |
Cancer - Oncology |
2015-10-00
|
FP-001 (leuprolide mesylate) |
advanced prostate carcinoma |
3 |
Foresee Pharmaceuticals (Taiwan, USA - DE) |
Cancer - Oncology |
2015-09-30
|
recAP - recombinant alkaline phosphatase |
hypophosphatasia |
preclinical |
AM-Pharma (The Netherlands) |
Rare diseases - Genetic diseases - Metabolic diseases |
2015-09-30
|
BioChaperone Lispro |
type 2 diabetes |
1b |
Adocia (France) Eli Lilly (USA - IN) |
Metabolic diseases |
2015-09-30
|
GEN-1 IL-12 in combination with Avastin® and Doxil® |
ovarian cancer |
1 |
Celsion (USA - NJ) |
Cancer - Oncology |
2015-09-30
|
GEN-1 IL-12 in combination with neoadjuvant chemotherapy |
ovarian cancer |
1 |
Celsion (USA - NJ) |
Cancer - Oncology |
2015-09-30
|
CHEMOSAT® Delivery System |
liver metastases from ocular melanoma |
|
Delcath Systems (USA - NY) |
Cancer - Oncology |